Association study of rs1801282 PPARG gene polymorphism and immune cells and cytokine levels in a Spanish pregnant women cohort and their offspring
Metadatos
Mostrar el registro completo del ítemAutor
García Ricobaraza, María; García Bermúdez, María Mercedes; Torres Espínola, Francisco J.; Segura Moreno, María Teresa; Campoy Folgoso, CristinaEditorial
Bmc
Materia
Pro12Ala PPARG polymorphism Immune system Pregnant mothers Newborn cord blood
Fecha
2020-12-30Referencia bibliográfica
García-Ricobaraza, M., García-Bermúdez, M., Torres-Espinola, F. J., Moreno, M. T. S., Bleyere, M. N., Díaz-Prieto, L. E., ... & Campoy, C. (2020). Association study of rs1801282 PPARG gene polymorphism and immune cells and cytokine levels in a Spanish pregnant women cohort and their offspring. Journal of Biomedical Science, 27(1), 1-9. [https://doi.org/10.1186/s12929-020-00694-3]
Patrocinador
Andalusian Ministry of Innovation and Science, Junta de Andalucía, Excellence Project P06-CTS-02341; Spanish Ministry of Economy and Competitiveness BFU2012-40254-C03-01; Abbott Laboratories, Granada, SpainResumen
Background: Peroxisome proliferator activated receptor gamma (PPARG ) belongs to the nuclear receptor superfamily
functioning as transcription factors to regulate cellular differentiation, development and metabolism. Moreover, it
has been implicated in the regulation of lipid metabolism, as well as the maturation of monocytes/macrophages and
the control of inflammatory reactions. The aim of this study was to evaluate the relationship between the Pro12Ala
(rs1808212) PPARG gene polymorphism on immune molecular and cellular components in mothers and their offspring
participating in the PREOBE study.
Methods: DNA from maternal venous blood samples at 24, 34 and 40 gestational weeks, plus cord blood samples
was extracted. Pro12Ala PPARG polymorphism genotyping was performed, and immune system markers were analyzed
by flow cytometry.
Results: Study findings revealed no effect of rs1808212 PPARG genotypes on innate immune parameters in mothers
and their offspring; however, CD4 + /CD8 + ratio were decreased at 24 and 34 weeks in pregnant women carrying the
CG (Pro12Ala) rs1808212 polymorphism, (p = 0,012 and p = 0,030; respectively). Only CD19 levels in peripheral blood
were significantly higher at delivery in pregnant women carrying the CC (Pro12Pro) genotype (p ≤ 0.001). Moreover,
there were statistically significant differences in leukocytes and neutrophils maternal levels at 34 weeks of gestation,
being lower in carriers of Pro12Ala genotype (p = 0.028 and p = 0.031, respectively).
Conclusions: Results suggest that Pro12Ala PPARG polymorphism may have an effect on some cell and immune
parameters in pregnant women during pregnancy and at time of delivery. However, newborn innate immune system
does not seems to be influenced by PPARG Pro12Ala polymorphism in cord blood.